Hyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it?

[41] Herbach N(2010)Further evidence that mutations in INS can be a rare cause of Maturity-onset diabetes of the young (MODY) BMC Med Genet 11 785-73

[42] Rathkolb B(2012)Early diabetes study group of I: minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births Acta Diabetol 49 390-24

[43] Kemter E(1997)Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas Diabetes 46 2265-51

[44] Pichl L(2016)Exenatide Is an effective antihyperglycaemic agent in a mouse model of Wolfram syndrome 1 J Diabetes Res 9 1616-92

[45] Klaften M(2014)Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia PLoS One 16 843-5

[46] de Angelis MH(1995)Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide Endocr Rev 60 1487-23

[47] Halban PA(2011)Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice Diabetes 58 14070-68

[48] Wolf E(2009)Inhibitory effects of leptin on pancreatic alpha-cell function Diabetes 54 e315-undefined

[49] Aigner B(2011)Leptin downregulates expression of the gene encoding glucagon in alphaTC1-9 cells and mouse islets Diabetologia 48 59-undefined

[50] Wanke R(1999)Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat Diabetes 105 undefined-undefined

[41] Herbach N(2010)Further evidence that mutations in INS can be a rare cause of Maturity-onset diabetes of the young (MODY) BMC Med Genet 11 785-73

[42] Rathkolb B(2012)Early diabetes study group of I: minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births Acta Diabetol 49 390-24

[43] Kemter E(1997)Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas Diabetes 46 2265-51

[44] Pichl L(2016)Exenatide Is an effective antihyperglycaemic agent in a mouse model of Wolfram syndrome 1 J Diabetes Res 9 1616-92

[45] Klaften M(2014)Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia PLoS One 16 843-5

[46] de Angelis MH(1995)Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide Endocr Rev 60 1487-23

[47] Halban PA(2011)Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice Diabetes 58 14070-68

[48] Wolf E(2009)Inhibitory effects of leptin on pancreatic alpha-cell function Diabetes 54 e315-undefined

[49] Aigner B(2011)Leptin downregulates expression of the gene encoding glucagon in alphaTC1-9 cells and mouse islets Diabetologia 48 59-undefined

[50] Wanke R(1999)Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat Diabetes 105 undefined-undefined